Zydus Cadila receives USFDA approval for Fingolimod capsules
Fingolimod is an immunomodulating drug. It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis
Fingolimod is an immunomodulating drug. It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
It is used to treat low blood pressure that causes severe dizziness or a lightheaded feeling.
Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, are indicated for the treatment of orthostatic dizziness
Granules now has a total of 37 ANDA approvals from US FDA (36 Final approvals and 1 tentative approvals).
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability
Subscribe To Our Newsletter & Stay Updated